問卷

TPIDB > Search Result

Search Result

篩選

List

640Cases

2022-09-01 - 2027-08-31

Phase III

Completed
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
4Sites

Recruiting4Sites

2024-10-04 - 2027-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-11-01 - 2025-10-31

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2023-07-01 - 2025-12-31

Others

Completed
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
3Sites

Recruiting3Sites

2021-10-01 - 2027-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-07-27 - 2026-09-30

Phase II

Active
xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
13Sites

Recruiting13Sites

2022-11-30 - 2027-03-31

Phase I/II

Completed
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    注射劑 注射液

Participate Sites
4Sites

Recruiting4Sites

2023-10-16 - 2027-06-30

Phase III

Completed
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
  • Condition/Disease

    severe eosinophilic asthma (EXHALE-3)

  • Test Drug

    tablets

Participate Sites
11Sites

Recruiting11Sites

2024-01-01 - 2025-12-31

Phase III

Completed
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)
  • Condition/Disease

    eosinophilic asthma (EXHALE-4)

  • Test Drug

    tabltes

Participate Sites
9Sites

Recruiting9Sites

2024-01-01 - 2025-09-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites